Zhongxin Finance, January 20 (Reporter Xie Yiguan) Recently, Changchun Hi-Tech, which has continuously dropped the limit, has confused more than 100,000 shareholders.
On the afternoon of the 20th, Changchun Hi-Tech released the latest response on the investor interaction platform, saying that the company and its branches and subsidiaries are currently in normal daily production and operation, the team is stable, and the repurchase plan is continuing to be implemented.
or affected by the centralized procurement of medicines in Guangdong Province
On January 19 and 20, Changchun Hi-Tech continued to drop by the limit.
As of the close on the 20th, the stock price was reported at 204.84 yuan, and the total market value was 82.9 billion yuan.
Changchun high-tech daily K chart.
According to market analysis, the stock price fluctuation this time was mainly due to the fact that the company's growth hormone products were included in Guangdong Province's centralized drug procurement.
The "Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement Documents" released on the website of the Guangdong Provincial Drug Trading Center on the 19th showed that a variety of recombinant human growth hormones are in the centralized procurement catalog, including the reorganized life of Changchun Jinsai Pharmaceutical, a subsidiary of Changchun High-tech Holdings. Long Hormone Injection (National Medicine Zhunzi S20050025).
Changchun High-tech responded on the interactive platform on the 19th that it was included in the centralized drug procurement. The company is currently actively researching policy regulations and will formulate a reasonable response plan. Currently, there is no specific impact expected.
On the 20th, Changchun Hi-Tech once again stated on the interactive platform that according to relevant documents, recombinant human growth hormone injection (water injection) and recombinant human growth hormone for injection (powder injection) were included in the scope of centralized procurement in the Guangdong Alliance area.
At present, the bidding process for this centralized drug procurement has not yet officially started, and the specific impact will also depend on the actual participation in the bidding, the results of the selection, the selection price, etc. The follow-up matters and the degree of impact on the company are still uncertain. There is no expectation that it will have a serious impact on the company's operating performance. The company will actively pay attention to the follow-up progress, carefully study the relevant documents and regulations, and formulate a reasonable implementation plan.
Screenshot from Investor Interactive Platform.
Investors lost more than 130,000 per capita in two days
According to the third quarterly report of Changchun High-tech in 2021, Changchun High-tech has a total of 150,705 shareholders. Based on the current total share capital of 400 million, the average number of shares held is about 2,654.
The decline stopped for two consecutive days, and the average floating loss of shareholders holding Changchun Hi-Tech was about 137,000 yuan.
If starting from the stock price high of 523 yuan in May 2021, as of January 20, the per capita loss will be about 844,000 yuan.
As a "medicine mao", Changchun Hi-Tech is heavily held by a number of medical funds, and the stock price has stopped falling for two consecutive days, which has also driven the net value of these medical funds to fall.
For example, the China Europe Healthcare Fund managed by well-known fund manager Gu Lan is an example.
It is worth mentioning that according to the iFinD data of Flush, as of November 23, 2021, China Europe Healthcare held a total of 5,517,200 shares in Changchun Hi-Tech, an increase of 418,000 shares compared with the end of the third quarter of 2021.
(Finish)